Home › Research › Mild cognitive impairment
Elevation of glutathione as a therapeutic strategy in Alzheimer disease
Pocernich CB, Butterfield DA.. Biochimica et biophysica acta, 2011-10-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD). AD and MCI brain and plasma display extensive oxidative stress as indexed by protein oxidation, lipid peroxidation, free radical formation, DNA oxidation, and decreased antioxidants. The most abundant endogenous antioxidant, glutathione, plays a significant role in combating oxidative stress. The ratio of oxidized to reduced glutathione is utilized as a measure of intensity of oxidative stress. Antioxidants have long been considered as an approach to slow down AD progression. In this review, we focus on the elevation on glutathione through N-acetyl-cysteine (NAC) and γ-glutamylcysteine ethyl ester (GCEE) as a potential therapeutic approach for Alzheimer disease. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
What this study adds
Evidence grade: Low
This is a narrative review. This review discusses oxidative stress in mild cognitive impairment and Alzheimer's disease and proposes raising levels of the antioxidant glutathione using N-acetyl-cysteine or gamma-glutamylcysteine ethyl ester as a possible treatment approach. It presents this as a potential strategy rather than an established therapy.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pocernich, C. B., & Butterfield, D. A. (2012). Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochimica et biophysica acta. https://doi.org/10.1016/j.bbadis.2011.10.003
Vancouver
Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochimica et biophysica acta. 2012. doi:10.1016/j.bbadis.2011.10.003. PMID: 22015471.
BibTeX
@article{pocernich2012-22015471,
author = {Pocernich, C. B. and Butterfield, D. A.},
title = {{Elevation of glutathione as a therapeutic strategy in Alzheimer disease}},
journal = {Biochimica et biophysica acta},
year = {2012},
doi = {10.1016/j.bbadis.2011.10.003},
pmid = {22015471},
url = {https://doi.org/10.1016/j.bbadis.2011.10.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD).
- The most abundant endogenous antioxidant, glutathione, plays a significant role in combating oxidative stress.
Why it matters
This review discusses oxidative stress in mild cognitive impairment and Alzheimer's disease and proposes raising levels of the antioxidant glutathione using N-acetyl-cysteine or gamma-glutamylcysteine ethyl ester as a possible treatment approach. It presents this as a potential strategy rather than an established therapy.
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 45 of the 96 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Biochimica et biophysica acta) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 347 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.7 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 57 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David Allan Butterfield: h-index 135 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Kentucky: institution h-index 824 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22015471) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 96 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.bbadis.2011.10.003
- PubMed: 22015471
- Original source →
- Free full text: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Mild cognitive impairment from nearby years
Also in Mild cognitive impairment
76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.